The Biotech CEO’s Guide to Your First FDA Meeting

Your first FDA meeting could shape the future of your entire development program.But many biotech teams prepare for it as a regulatory event rather than a strategic decision point.They focus on the meeting request, briefing package, questions, and presentation-without first agreeing on what the company needs to learn, which decisions FDA's feedback must inform, or how the program will respond if the agency takes a different view.The Biotech CEO's Guide to Your First FDA Meeting offers a practical, executive-level framework for preparing more strategically.Written by Nilou Sarah Arden, PhD-a former FDA regulator and global biopharma regulatory leader-the guide helps biotech founders, CEOs, executives, and development teams look beyond the mechanics of the meeting and ask a more important question: What must this FDA interaction enable us to decide?Inside, you will learn how to: - Define the decisions for which your company needs FDA input - Identify the most consequential uncertainties in your development plan - Prioritize questions that could materially change the program - Distinguish evidence, assumptions, beliefs, and unresolved uncertainty - Integrate CMC, nonclinical, clinical, and regulatory strategies - Recognize which questions should not be asked-or should not be asked yet - Build a briefing package that supports clear, decision-useful feedback - Prepare for disagreement, conditional advice, and unexpected responses - Decide which commitments should be made now and which can wait - Align the leadership team before entering the meetingThe guide also includes: - A one-page FDA meeting strategy - A five-minute strategic-readiness diagnostic - A CEO checklist for final preparation - A post-meeting framework for turning regulatory feedback into decisions, actions, and organizational learningThis is not a technical manual for writing an FDA briefing package. It is a field guide for leading the decisions around one.Whether your company is preparing for a pre-IND meeting, an initial regulatory interaction, or another consequential FDA milestone, this guide will help you connect regulatory strategy to the wider development pathway-including evidence, manufacturing, clinical planning, capital, sequencing, risk, and future options.Because a successful FDA meeting is not simply one that goes smoothly.It is one that helps the company make better decisions.Part of the Cambase Executive Field Guides series: practical intelligence for the decisions shaping the path from science to patients.